Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.
Allogeneic HCT improves 5-year survival for patients over 60 with AML in CR1December 2018
Devillier R et al. ASH Annual Meeting 2018 - Results from a recent multicenter analysis support hematopoietic cell transplantation (HCT) as a curative option for patients over 60 with acute myeloid leukemia. Researchers found that HCT improved relapse-free survival and overall survival for older patients at 5 years when compared with patients who did not undergo HCT. (Devillier R et al. 2018 ASH Annual Meeting)
Adding genomic data to new prognostic model improves predictors of post-HCT outcomes in patients with MDSDecember 2018
Nazha A, et al. ASH Annual Meeting 2018 - Researchers have developed a new personalized hematopoietic cell transplantation (HCT) outcomes prediction model for patients with myelodysplastic syndromes that incorporates both genomic and clinical data. The new genomic-clinical model can help physicians better identify patients who may or may not benefit from HCT.